Secukinumab Produces Effective Skin Clearance in Late-Stage Trials

Novartis’s experimental psoriasis drug, secukinumab, demonstrated sustained efficacy in its final late-stage trials, the manufacturer revealed at the 72nd Annual Meeting of the American Academy of Dermatology (AAD) held in Denver, CO.

In a pair of phase 3 trials, psoriasis patients experienced almost clear skin at 12 weeks after receiving 300 mg of secukinumab, compared to their placebo counterparts. Additionally, the 300 mg dosage group showed clinically relevant improvements over the 150 mg participants in both the FEATURE and JUNCTURE studies.

The patients also had no qualms about self-administering the drug, according to their self-reports on the Self-Injection Assessment Questionnaire (SIAQ), which covers overall experience, feelings about injections, self-confidence, satisfaction with self-injection, injection-site reactions, ease of use, and self-image before and after treatment.

“It is important that people living with psoriasis, a chronic skin disease, have highly effective and safe treatments they can conveniently self-administer,” Tim Wright, Global Head of Development for Novartis, said in a press release. “These exciting results from our specialty dermatology portfolio show that secukinumab, the first interleukin-17A (IL-17A) inhibitor with regulatory submissions completed, had similar efficacy in clearing skin with a convenient pre-filled syringe and autoinjector pen as in the landmark FIXTURE study, where it was significantly superior to Enbrel, a biologic psoriasis therapy approved 10 years ago.”

Secukinumab’s efficacy was preserved over the full 1-year trial period, with the 300 mg patient group experiencing almost clear skin at the end of the study.

The most common side effects reported across all treatment groups were diarrhea, nasopharyngitis, headache, and pruritus.

Most Popular

Recommended Reading

Public health ad campaigns are not so prevalent as they were a few decades ago. Primary care doctors in South Carolina have taken over where Madison Avenue left off. Cardiovascular disease has since fallen.
Occupational morbidity and mortality are elevated across food system industries compared with nonfood system industries, according to a study published online May 12 in the Journal of Occupational and Environmental Medicine.

Study results presented at the 2015 Congress of the European League Against Rheumatism show treatment with apremilast can improve common, painful manifestations of psoriatic arthritis.
Endovascular treatment should be used to treat certain stroke victims, according to new guidelines issued by the American Heart Association and American Stroke Association.